An observational study in Choledocholithiasis, Cholelithiasis and Difficult Biliary Cannulation, sponsored by Minia University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Minia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Choledocholithiasis with a site in Egypt — 2 open to participants now, 2 under way, none of them phase 3. Choledocholithiasis · Egypt.
Among the 12 studies in Choledocholithiasis with a site in Egypt, this one is the only one that started in 2026, is one of 3 observational ones, and was the 12th registered.
109 studies on the registry are indexed under Choledocholithiasis; 24 are open to participants now.
Browse Choledocholithiasis studies →2 of the 12 studies in Choledocholithiasis with a site in Egypt are open now. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–75
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 18 Choledocholithiasis studies recruiting now, 10 (56%) set no upper age limit and 1 (6%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 190 is close to the median of 200 across 31 observational studies indexed under Choledocholithiasis.
Median enrollment 200 across the 9 interventional studies, 115 across the 3 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 8 most frequent:
Minia University is the lead sponsor of 373 studies on the registry; 120 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Minia University has 2 studies filed under Choledocholithiasis — fewer than ten, so there is no comparison to draw.
1 of the studies in Choledocholithiasis with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07944300Minia UniversityUsing MRCP Anatomy to Predict Difficult Bile Duct Cannulation During Single-Stage Laparoendoscopic Rendezvous for Gallbladder and Bile Duct Stones | 2027-08-20 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Choledocholithiasis with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether measurements of bile duct and duodenal anatomy on a routine pre-operative MRCP scan (magnetic resonance cholangiopancreatography, an MRI of the bile and pancreatic ducts) can predict difficult bile duct cannulation during ERCP in adults with gallbladder stones and bile duct stones who are treated in a single operation called laparoendoscopic rendezvous.
The main questions it aims to answer are:
The researchers expect that anatomy measured on the MRCP scan alone, without any clinical or blood-test information, will predict difficult cannulation well enough to guide when the rendezvous wire should be used first.
Participants already scheduled for laparoendoscopic rendezvous as part of their regular medical care will:
Difficult cannulation is the main procedural cause of pancreatitis after ERCP and of failed stone clearance. The rendezvous wire can prevent it, but it is currently used either in every patient or only after difficulty has already occurred. A score calculated from the scan before surgery could allow the wire to be used first in the patients who need it. The study does not change any treatment decision, and the score will need testing in other hospitals before it is used in routine care.
BACKGROUND AND RATIONALE
Common bile duct (CBD) stones are present in a clinically important minority of patients undergoing cholecystectomy. Management is either two-stage (preoperative endoscopic sphincterotomy and duct clearance followed by laparoscopic cholecystectomy) or single-stage (laparoscopic CBD exploration or laparoendoscopic rendezvous, LERV). Randomized and pooled data show equivalent duct clearance with fewer procedures, a shorter cumulative hospital stay and, in several series, less post-ERCP pancreatitis with the rendezvous route.
In LERV, laparoscopic cholecystectomy is combined with intraoperative ERCP: a guidewire passed antegrade through the opened cystic duct and across the papilla is captured by the duodenoscope and guides the sphincterotome into the bile duct, avoiding repeated blind probing of the papilla and precut sphincterotomy. The antegrade wire converts a potentially difficult cannulation into a trivial one, so its benefit is greatest where the papilla would otherwise be difficult to cannulate; yet it is currently used either in every case or reactively, after difficulty has been encountered and the papilla has already been repeatedly instrumented.
The European Society of Gastrointestinal Endoscopy (ESGE) defines difficult biliary cannulation of a native papilla as more than 5 minutes of attempted cannulation, more than 5 attempts or more than one unintended pancreatic duct cannulation. The composite is the strongest procedure-related risk factor for post-ERCP pancreatitis and also predicts advanced access techniques, longer fluoroscopy, incomplete duct clearance and repeat procedures. Existing prediction tools are largely retrospective, rely on endoscopic descriptors of the papilla that are unavailable before the procedure, or were developed in mixed populations that include malignant strictures, altered anatomy and previously instrumented papillae.
MRCP is already obtained in nearly all patients in this pathway, so the index test adds no burden, cost or risk, and three-dimensional navigator-gated acquisitions allow reproducible measurement of the terminal biliary geometry that the endoscopist must negotiate. Features with a coherent mechanical rationale for impeding cannulation include an acute choledochoduodenal angle, abrupt distal CBD angulation (hockey-stick or sigmoid configuration), a long intramural segment, a periampullary diverticulum with the papilla inside it or on its rim (Boix types I and II), and distal stone impaction.
KNOWLEDGE GAP
No prospective study has developed a preoperative MRCP-based prediction model for difficult biliary cannulation in a homogeneous cohort managed by single-stage LERV, with pre-specified measurement definitions, blinded duplicate image reading, formal internal validation and TRIPOD-compliant reporting. A 2026 retrospective cohort (Kahwagi et al., Cureus) associated MRCP-derived distal CBD diameter and choledochoduodenal angulation with cannulation difficulty, supporting plausibility, but did not standardize measurement prospectively, could not guarantee reader blinding, developed no penalized, validated and calibrated model, and was not conducted in the rendezvous pathway, where the decision a model would inform (whether to deploy the antegrade wire first) actually exists. Because the antegrade wire provides a guaranteed, immediate rescue, a short cannulation phase capped at the ESGE thresholds can be observed here safely and ethically, without precut sphincterotomy or prolonged instrumentation.
OBJECTIVES
Primary objective: to develop and internally validate a multivariable model that predicts, from preoperative MRCP findings alone, the probability of difficult biliary cannulation of the native papilla during the endoscopic phase of LERV in adults with concomitant cholelithiasis and choledocholithiasis. The model contains three pre-specified MRCP parameters and no clinical, biochemical, operator or institutional variable, so that the resulting score can be computed in full from a single investigation at the time of radiological reporting.
Secondary objectives are to quantify the independent association of each MRCP feature in the primary model with difficult cannulation; to derive pre-specified and optimal cut-offs for the continuous morphometric predictors; to determine the inter-observer and intra-observer reproducibility of every candidate MRCP measurement; and to relate the predicted probability of difficult cannulation to procedure time, fluoroscopy, duct clearance, post-ERCP pancreatitis and length of stay. Exploratory objectives are to estimate the incremental value of each remaining candidate MRCP feature, to test whether a composite geometric index outperforms its components, to compare model performance between endoscopists above and below 300 lifetime ERCPs, and to estimate how many participants a pre-specified decision rule would assign to wire-first rendezvous, with the expected reduction in papillary instrumentation.
STUDY DESIGN
Prospective, single-center, observational diagnostic prediction-model development study with bootstrap internal validation, reported according to TRIPOD (including TRIPOD+AI where applicable) for model development and STARD 2015 for the diagnostic accuracy components, with a SPIRIT-informed protocol. Consecutive eligible patients undergo the index test (MRCP) as part of routine preoperative assessment, followed by the reference standard (a standardized, capped standard cannulation phase within the clinically indicated LERV). No treatment is allocated, randomized or withheld; the only standardization introduced is the sequence and timing of the cannulation phase, which lies within accepted practice.
Key design decisions: the standard cannulation phase is capped at the ESGE definition of difficulty, so the outcome is observable while no participant is instrumented beyond the point at which guidelines already recommend a change of technique; difficulty is defined by the ESGE composite, so pancreatic duct trauma is captured; predictors are restricted to MRCP so that the model is computable at the moment of decision, does not depend on a clinical state that changes between scan and operation, and transports across institutions with different biochemical thresholds and case mix; endoscopic papillary descriptors are excluded because they are unavailable before the procedure; and penalized regression on a pre-specified predictor set with bootstrap internal validation replaces univariable screening, stepwise selection and split-sample validation.
SETTING AND PARTICIPANTS
Liver and GIT Hospital, Faculty of Medicine, Minia University, Egypt, a tertiary referral center for hepatopancreatobiliary disease in which the single-stage LERV pathway is established (the unit's prospective LERV cohort is registered as NCT07008170). Procedures are performed in a hybrid operating room, or an operating room equipped with a mobile C-arm and a therapeutic duodenoscope, by consultant hepatobiliary surgeons whose lifetime ERCP volume is recorded at study entry.
Consecutive patients are identified at the hepatobiliary outpatient clinic and the emergency surgical intake. A research team member not directly responsible for the patient's care obtains written informed consent, allowing at least 24 hours for consideration wherever the clinical timetable permits; consent covers participation, the use of anonymized imaging and intraoperative video for the study, and 90-day follow-up. Participants may withdraw at any time without any effect on their treatment. A screening log records every patient assessed and the reasons for any exclusion or non-enrollment.
INDEX TEST: MRCP
Acquisition: 1.5 T scanner with a phased-array body coil after a fast of at least 6 hours; 200 mL of pineapple or blueberry juice 10 minutes before the examination as a negative oral contrast agent; no intravenous gadolinium; 3 T examinations are recorded as such. Minimum protocol: (1) axial and coronal breath-hold T2 HASTE/SSFSE, 4-5 mm, with and without fat saturation; (2) axial T1 in-phase and opposed-phase gradient echo; (3) coronal thick-slab single-shot RARE MRCP, 40-60 mm slab, acquired at 15° radial increments through 180° around the CBD axis; (4) respiratory-triggered navigator-gated 3D T2 turbo spin-echo MRCP with near-isotropic 1.0-1.4 mm voxels in the coronal-oblique plane along the extrahepatic duct, reconstructed as thin partitions and maximum intensity projections (the primary morphometric dataset); (5) diffusion-weighted imaging (b = 0, 500 and 800 s/mm²); (6) thin-section axial T2 through the second part of the duodenum.
Post-processing: curved planar reformat along the CBD centerline; oblique-coronal reformat containing the terminal 20 mm of the duct and the long axis of the second part of the duodenum (D2); axial reformat through the papillary orifice. Annotated reformats are archived for re-examination.
CANDIDATE PREDICTORS
All candidate variables are recorded in every participant; three form the primary model and the remainder are analyzed in exploratory extended models.
IMAGE READING, BLINDING AND REPRODUCIBILITY
Two radiologists read all examinations independently, in randomized order, on a locked structured electronic form that enforces the definitions above and carries plausibility ranges. Both are blinded to intraoperative and endoscopic findings, to the outcome and to each other's measurements. The routine clinical MRCP report remains available to the treating team and follows the department's standard template, which excludes angles, intramural segment length and Boix typing; the structured morphometric dataset is held in a separate access-controlled database and is not released to the endoscopist or surgeon before the end of the cannulation phase.
Before recruitment, both readers complete a calibration exercise on 20 non-study MRCP examinations and produce a measurement atlas appended to the protocol. A random sample of 50 study examinations is re-read by the first reader at least 8 weeks later, blinded to the original values. Agreement is quantified by the intraclass correlation coefficient (ICC; two-way random effects, absolute agreement, single measures) for continuous variables and Cohen's kappa (weighted where ordinal) for categorical variables. Any candidate predictor with an ICC or kappa below 0.60, or whose 95% confidence interval includes 0.50, is excluded before any association with the outcome is examined. Retained continuous variables use the mean of the two readers; categorical variables use the consensus value adjudicated by a third reader.
REFERENCE STANDARD: STANDARDIZED LERV AND THE CANNULATION PHASE
Operative sequence: (1) general anesthesia in the supine, split-leg or French position; antibiotic prophylaxis per institutional policy; rectal indomethacin or diclofenac 100 mg at induction unless contraindicated, as recommended by ESGE guidance. (2) Standard four-port laparoscopic cholecystectomy with dissection of the hepatocystic triangle to the critical view of safety, photographically documented in every case. (3) The cystic duct is clipped at the gallbladder end, a transverse ductotomy is made, the duct is milked toward the gallbladder, a 5 Fr catheter is introduced and secured, and intraoperative cholangiography confirms the diagnosis and documents ductal anatomy and stone position. (4) The guidewire is not advanced across the papilla at this stage; it is held proximal to the terminal duct. (5) The duodenoscope is positioned in the short scope position with the papilla in view and the standard cannulation phase begins. (6) Duct clearance follows: sphincterotomy where indicated, balloon or basket extraction, occlusion cholangiography and choledochoscopy where required. (7) The cystic duct is clipped or sutured, the gallbladder retrieved, hemostasis confirmed and the abdomen closed; drain placement is at the surgeon's discretion and is recorded.
Standard cannulation phase: wire-guided cannulation of the native papilla with a sphincterotome and a 0.025- or 0.035-inch hydrophilic-tip guidewire, using the endoscopist's routine technique. Timing starts at first contact of the device with the papilla and is recorded by an independent observer with a digital stopwatch, with parallel video recording. The phase ends at the first of: selective deep biliary access confirmed by wire position or opacification of the biliary tree; 5 minutes of cumulative cannulation time; a sixth cannulation attempt being required; or a second unintended pancreatic duct cannulation or opacification. If the phase ends without biliary access, the outcome is recorded as difficult cannulation and the surgeon immediately advances the transcystic guidewire antegrade across the papilla to complete the rendezvous. Precut sphincterotomy, transpancreatic sphincterotomy, the double-guidewire technique and pancreatic stent placement are not used to obtain access before the rendezvous wire has been deployed. The phase is terminated early if the anesthesiologist or operating surgeon judges that continuation is not in the participant's interest; the reason is documented and examined in a sensitivity analysis.
Operational definitions: an attempt is a sustained contact with the orifice with intent to enter, ending in withdrawal or scope repositioning; cumulative cannulation time sums the periods of device engagement with the papilla, with the clock stopped (and stopped periods recorded) for scope repositioning, equipment exchange and radiographic acquisition; unintended pancreatic duct cannulation is guidewire entry into, or contrast opacification of, the pancreatic duct when biliary access was intended; selective deep biliary access is a guidewire above the cystic duct confluence or unequivocal intrahepatic opacification.
BLINDING OF OUTCOME ASSESSMENT AND PROCEDURAL DATA
The independent observer and the endoscopist are blinded to the structured MRCP morphometry. Neither can be blinded to the routine clinical MRCP report, which establishes the indication; this residual unblinding is acknowledged and mitigated by the report template. Every procedure video is reviewed afterwards by a second assessor, blinded to the MRCP data and to the original timings, who independently re-derives cannulation time, attempt count and pancreatic duct passes; disagreement in classification of the primary outcome is resolved by consensus with a third assessor. Agreement between real-time and video-derived classification is reported as a kappa statistic and is a key quality indicator. Procedural data recorded for description and stratified analyses include coded endoscopist identity, lifetime ERCP volume, duodenoscope and device, short scope position, antispasmodic use, duodenal peristalsis, papillary morphology (Haraldsson classification) and endoscopically visible periampullary diverticulum (for comparison with MRCP, not as a predictor).
OTHER DATA COLLECTED
None of the following enters any model; these variables describe the cohort and define the subgroups of the sensitivity analyses: demographics and comorbidity (including ASA grade and Charlson index); presenting syndrome, Tokyo Guidelines 2018 grade and previous biliary inflammation; preoperative laboratory tests, with amylase or lipase at 4 and 24 hours after the procedure; ultrasonography; operative and endoscopic details (phase times, Nassar or Parkland grade, cystic duct handling, sphincterotomy, extraction, residual stone); and 30- and 90-day review.
SAMPLE SIZE
Sample size follows the criteria of Riley and colleagues for developing a prediction model with a binary outcome, assuming an outcome proportion of 0.33 and a C-statistic of 0.75 (Cox-Snell R² 0.167; maximum 0.719). A three-parameter model requires 147 evaluable participants for a uniform shrinkage factor of at least 0.90 (142-155 across outcome proportions of 0.30-0.35) and 75 for optimism in Nagelkerke R² of no more than 0.05. A total of 190 participants will be enrolled, allowing for approximately 10% attrition through non-diagnostic MRCP, conversion before the cannulation phase, protocol deviation or withdrawal. The resulting 171 evaluable participants (about 56 events; about 19 per parameter; expected shrinkage 0.91) estimate the overall outcome proportion within about ±0.07.
After 90 participants, the statistician reviews the outcome frequency alone; if it falls materially below 0.30, the sample size is reassessed through a protocol amendment. No interim analysis of predictor-outcome associations is performed.
STATISTICAL ANALYSIS PLAN
General: the plan is finalized before database lock and before any predictor-outcome association is examined. Analyses use R version 4.4 or later (rms, mice, glmnet, pROC, riskRegression, dcurves, pmsampsize), with code archived alongside the dataset. A two-sided alpha of 0.05 applies to descriptive and secondary comparisons; model development is not framed as hypothesis testing, and comparisons by outcome status are descriptive only and never used to select predictors.
Predictor handling: stage 1, blind to the outcome, retains a candidate only if its ICC or kappa is at least 0.60, its prevalence is at least 10% for binary variables (or it can be collapsed into a category meeting that threshold), and it has a pre-specified mechanistic rationale; closely related constructs are reduced on reproducibility, not on association with the outcome. Stage 2 is the pre-specified 3-parameter MRCP prediction model, with the deputy in brackets substituted if a variable fails stage 1: (1) choledochoduodenal angle, linear [dichotomized at 130°]; (2) periampullary diverticulum with the papilla inside it or on its rim (Boix types I-II) versus none or type III [presence versus absence of a diverticulum]; (3) maximum CBD diameter, linear [distal CBD diameter 10 mm above the orifice]. They are pre-specified on prior evidence: choledochoduodenal angulation and CBD diameter in the published MRCP cohort, and periampullary diverticulum in the endoscopic literature. The remaining candidates (distal CBD angulation, intramural segment length, impacted distal or intramural stone, stone-to-duct ratio, papillary azimuth and Boix type III) are each added singly to the model in exploratory extended models. No clinical, biochemical, operator or institutional variable enters any model. Univariable p-value screening and stepwise selection are prohibited, and continuous predictors are not dichotomized except as listed deputies. Linearity is examined graphically, and a 3-knot spline for the choledochoduodenal angle is examined as a sensitivity analysis. The primary model has no interaction terms; one exploratory interaction (diverticulum type × choledochoduodenal angle) is pre-specified.
Missing data: missingness is tabulated for every variable and, assuming data are missing at random, handled by multiple imputation by chained equations (30 datasets; imputation model including the MRCP candidate predictors and the outcome only; predictive mean matching for continuous variables), with estimates combined by Rubin's rules and a complete-case sensitivity analysis. A non-diagnostic MRCP is an exclusion from the primary analysis, not missing data, and those participants are described separately.
Model: a single multivariable logistic regression of the outcome on the three MRCP parameters, the sole basis of the risk score; no comparator model containing clinical variables is fitted. Ridge penalization is the primary approach, with the penalty selected by 10-fold cross-validation repeated 25 times and coefficients reported on the original scale; elastic net (alpha 0.5) and unpenalized maximum likelihood with post-hoc uniform shrinkage are pre-specified alternatives, all three reported if they disagree materially, with the ridge model retained as primary.
Performance and internal validation: discrimination by the C-statistic with 95% CI; calibration by calibration-in-the-large, the calibration slope, a loess flexible calibration curve and the estimated calibration index (calibration being the primary performance criterion, reported in the abstract alongside discrimination); overall performance by the Brier score, scaled Brier score and Nagelkerke R². Optimism is estimated by bootstrapping with 1,000 replicates, repeating the entire modeling procedure, including penalty selection, in each replicate. The bootstrap uniform shrinkage factor is applied to the coefficients and the intercept is re-estimated so that the mean predicted probability equals the observed proportion.
Clinical utility and accuracy: decision curve analysis compares the net benefit of the MRCP prediction model with treating all participants as difficult (universal wire-first rendezvous) and with treating none, across threshold probabilities of 5% to 60%; a low threshold is justified because a false positive simply receives the antegrade wire first, and the pre-specified illustrative threshold is 20%. For each continuous morphometric predictor, sensitivity, specificity, predictive values and likelihood ratios are reported at the pre-specified threshold and at the Youden-optimal threshold, the latter with a bootstrap confidence interval and flagged as data-derived.
Secondary and sensitivity analyses: count outcomes by negative binomial regression; skewed continuous procedural outcomes by linear regression on the log scale; time to selective access by Cox regression with administrative censoring at 300 seconds. Sensitivity analyses exclude participants with acute cholangitis; exclude early termination of the cannulation phase for clinical reasons; evaluate performance separately for endoscopists with 300 or more and fewer than 300 lifetime ERCPs; restrict to examinations acquired at 1.5 T; use the video-derived instead of the real-time outcome classification; and repeat the analysis on complete cases.
MODEL EQUATION AND RISK SCORE
The primary model is logit(p) = b0 + b1x1 + b2x2 + b3x3, where p is the probability of difficult biliary cannulation and x1 to x3 are the three MRCP-derived parameters, with the shrunken coefficients obtained after internal validation; no clinical, biochemical or operator term appears in the equation. The intercept, coefficients, shrinkage factor and variance-covariance matrix will be published in full. An integer points score is derived by scaling each coefficient to the smallest absolute coefficient and rounding, with total points mapped to predicted probability, so that the reporting radiologist can compute the score at the workstation and append it to the MRCP report.
The anticipated direction of each predictor is fixed before analysis: risk is expected to rise with a more acute choledochoduodenal angle (per 10° reduction) and with a diverticulum that contains the papilla or carries it on its rim, and to fall with a larger maximum CBD diameter (per 1 mm). A reversed coefficient will be reported prominently as a possible signal of collinearity or measurement failure.
Predicted probabilities are grouped into pre-specified strata, low (\<15%), intermediate (15-40%) and high (>40%), with the observed outcome frequency and exact 95% CI in each. The associated management implications (standard cannulation first; standard cannulation first with a lowered conversion threshold and a senior endoscopist available; wire-first rendezvous) are illustrative hypotheses for a future impact study and are not tested here; clinical use requires external validation followed by a randomized impact study. Outputs are a nomogram, a points-to-probability table formatted as an MRCP report addendum and a free web calculator that takes only the three imaging inputs and discloses the coefficients.
QUALITY ASSURANCE AND SAFETY
Before the first enrollment, the radiologists complete the calibration exercise and measurement atlas, the independent observers complete a timing exercise on 10 recorded procedures against a reference, and all investigators complete Good Clinical Practice training. Each quarter the chief investigator verifies 10% of case report forms against source documents, focusing on the primary outcome, cannulation timings and the adverse event log; any systematic discrepancy triggers 100% source data verification for the affected period.
All adverse events within 30 days are recorded, graded by the Clavien-Dindo classification and classified as related or unrelated to the procedure and as expected or unexpected. Post-ERCP pancreatitis, perforation, clinically significant bleeding and cholangitis are reported to the Research Ethics Committee in the periodic safety report; any death within 30 days and any event of Clavien-Dindo grade IV or above is reported within 7 days. The capped phase, the exclusion of advanced access techniques before the rendezvous wire and universal rectal NSAID prophylaxis are expected to reduce papillary trauma relative to unstandardized practice.
ETHICS
Approved by MUFMIRB (approval number 2227:11/26, November 4, 2026) and conducted in accordance with the Declaration of Helsinki, ICH-GCP and Egyptian Law No. 214 of 2020, with annual reporting and prior approval of amendments. Participants receive no payment and incur no additional cost. The study is investigator-initiated and unfunded, and the investigators declare no conflict of interest.
Consecutive adults with symptomatic cholelithiasis and MRCP-confirmed concomitant choledocholithiasis with a native papilla, scheduled for single-stage laparoendoscopic rendezvous at the Liver and GIT Hospital, Minia University, Minia, Egypt, a tertiary referral center for hepatopancreatobiliary disease. Patients are identified at the hepatobiliary outpatient clinic and the emergency surgical intake; every patient assessed is entered in a screening log with the reason for any exclusion or non-enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with symptomatic cholelithiasis and MRCP-confirmed concomitant choledocholithiasis with a native papilla, scheduled for single-stage laparoendoscopic rendezvous (LERV) as part of routine care. Every participant follows the same pathway: a routine preoperative MRCP (the index test), read in duplicate by two blinded radiologists using pre-specified morphometric definitions, followed by LERV in which a standard retrograde cannulation phase, capped at the ESGE difficult-cannulation thresholds, precedes deployment of the transcystic antegrade rendezvous guidewire (the reference standard). No treatment is allocated, randomized or withheld by the study.
Diagnostic Test: Magnetic resonance cholangiopancreatography (MRCP) with structured blinded morphometry · Procedure: Single-stage laparoendoscopic rendezvous with a standardized, capped cannulation phase
Routine preoperative MRCP within 14 days before surgery on a 1.5 T scanner (3 T recorded as a covariate) after a fast of at least 6 hours, with 200 mL of pineapple or blueberry juice as negative oral contrast and no gadolinium. Minimum protocol: axial and coronal T2 HASTE/SSFSE, axial T1 in-phase and opposed-phase, coronal thick-slab RARE MRCP at 15° radial increments, respiratory-triggered navigator-gated 3D T2 turbo spin-echo MRCP (near-isotropic 1.0-1.4 mm voxels), diffusion-weighted imaging and thin-section axial T2 through the second part of the duodenum. Two radiologists, blinded to the outcome and to each other, measure the pre-specified terminal biliary geometry, periampullary duodenum, and ductal caliber and stone variables on curved planar, oblique-coronal and axial reformats using a locked structured form. Measurements are withheld from the operating team until the cannulation phase has ended.
Also known as: MRCP /MR cholangiopancreatography /3D navigator-gated MRCP
Performed for clinical indication under general anesthesia by consultant hepatobiliary surgeons. Laparoscopic cholecystectomy to a photographed critical view of safety; cystic ductotomy, 5 Fr transcystic catheter and intraoperative cholangiography, with the guidewire held proximal to the terminal duct. With the duodenoscope in the short position, wire-guided cannulation of the native papilla is attempted until biliary access or until an ESGE threshold is reached (5 minutes of cumulative cannulation time, a sixth attempt required, or a second unintended pancreatic duct cannulation); the transcystic guidewire is then advanced antegrade across the papilla and captured. Precut, transpancreatic sphincterotomy, double-guidewire and pancreatic stent techniques are not used before the rendezvous wire. Duct clearance, completion cholangiography and closure follow. Rectal indomethacin or diclofenac 100 mg is given at induction unless contraindicated.
Also known as: LERV /Laparoendoscopic rendezvous/ Laparoscopic cholecystectomy with intraoperative ERCP
Difficult biliary cannulation of the native papilla (ESGE composite definition)
Proportion of participants with difficult biliary cannulation during the standard retrograde cannulation phase of laparoendoscopic rendezvous, defined as any of the following before selective deep biliary access: (a) more than 5 minutes of cumulative cannulation time from first contact of the cannulating device with the papilla; (b) more than 5 cannulation attempts; or (c) more than one unintended pancreatic duct cannulation or opacification. Recorded in real time by an independent observer blinded to the structured MRCP morphometry and re-adjudicated from the procedure video by a second blinded assessor, with disagreement resolved by a third. Binary outcome (yes/no); this is the outcome predicted by the MRCP prediction model.
Time frame: Intraoperative (Day 0), during the standard cannulation phase, which is capped at 5 minutes of cumulative cannulation time
Number of cannulation attempts
Count of attempts during the standard cannulation phase. An attempt is a sustained contact of the device with the papillary orifice with intent to enter, ending in withdrawal from the orifice or scope repositioning; repositioning the wire within one sustained contact is not a new attempt.
Time frame: Intraoperative (Day 0), during the standard cannulation phase
Number of unintended pancreatic duct cannulations
Count of guidewire entries into, or contrast opacifications of, the main pancreatic duct when biliary access was intended, during the standard cannulation phase.
Time frame: Intraoperative (Day 0), during the standard cannulation phase
Complete common bile duct clearance
Proportion of participants with no residual filling defect on completion (occlusion) cholangiography and, where performed, on choledochoscopy at the end of the procedure.
Time frame: End of the procedure (Day 0)
Failed antegrade transcystic guidewire passage
Proportion of participants in whom the transcystic guidewire cannot be advanced across the papilla into the duodenum within 10 minutes, or in whom antegrade passage is abandoned for anatomical reasons.
Time frame: Intraoperative (Day 0)
Duration of the endoscopic phase
Minutes from duodenoscope insertion to duodenoscope withdrawal.
Time frame: Intraoperative (Day 0)
Total operative time
Minutes from skin incision to skin closure.
Time frame: Intraoperative (Day 0)
Rendezvous wire capture time
Seconds from the first appearance of the antegrade guidewire in the duodenal lumen to its withdrawal through the working channel of the duodenoscope, in participants who cross over to rendezvous.
Time frame: Intraoperative (Day 0)
Crossover to the antegrade rendezvous guidewire
Proportion of participants in whom the transcystic antegrade guidewire is advanced across the papilla because a stopping criterion of the standard cannulation phase was reached without selective biliary access.
Time frame: Intraoperative (Day 0), at the end of the standard cannulation phase
Cumulative cannulation time
Seconds from first contact of the cannulating device with the papilla to confirmed selective deep biliary access, summing the periods of device engagement and excluding stopped periods for scope repositioning, equipment exchange and radiographic acquisition; administratively censored at 300 seconds. Timed by an independent observer with a digital stopwatch and verified on the procedure video.
Time frame: Intraoperative (Day 0), during the standard cannulation phase (maximum 300 seconds)
Post-ERCP pancreatitis
Proportion of participants with new or worsened abdominal pain and serum amylase or lipase at least three times the upper limit of normal more than 24 hours after the procedure, requiring admission or prolongation of hospital stay (consensus criteria), with severity graded by the consensus criteria and by the revised Atlanta classification. Serum amylase and lipase are sampled at 4 and 24 hours after the procedure.
Time frame: From the end of the procedure to 30 days postoperatively
Other procedure-related adverse events
Proportion of participants with bleeding, perforation, cholangitis, bile leak, wound infection or cardiopulmonary events, each graded by the Clavien-Dindo classification and classified as related or unrelated to the procedure.
Time frame: Up to 30 days after surgery
Conversion or abandonment of the single-stage approach
Proportion of participants converted to open surgery, or in whom the single-stage approach is abandoned in favor of staged postoperative ERCP.
Time frame: Intraoperative (Day 0)
Postoperative length of hospital stay
Number of postoperative nights from surgery to discharge.
Time frame: From surgery to hospital discharge, assessed up to 90 days
Retained or recurrent common bile duct stones
Proportion of participants with symptomatic or imaging-confirmed choledocholithiasis after the index procedure, assessed at outpatient review with liver function tests and ultrasonography where clinically indicated.
Time frame: Up to 90 days after surgery (reviews at 30 and 90 days)
Association between the predicted probability from the MRCP prediction model and procedural outcomes
Association of the predicted probability of difficult cannulation from the MRCP prediction model with total operative time, endoscopic phase duration, fluoroscopy time and dose, complete duct clearance, post-ERCP pancreatitis and length of stay, estimated by regression: linear regression on the log scale for skewed continuous outcomes, logistic regression for binary outcomes and negative binomial regression for counts.
Time frame: From surgery (Day 0) to 30 days after surgery
Optimism-corrected C-statistic of the MRCP prediction model
Discrimination of the MRCP prediction model (3 pre-specified MRCP-derived parameters and no clinical variables; ridge-penalized logistic regression) for difficult biliary cannulation, expressed as the C-statistic (area under the ROC curve; 0.5 indicates no discrimination and 1.0 perfect discrimination) with 95% CI, corrected for optimism by bootstrap internal validation with 1,000 replicates in which the entire modeling procedure is repeated.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Optimism-corrected calibration slope of the MRCP prediction model
Slope of the logistic recalibration of the observed outcome on the linear predictor of the MRCP prediction model (ideal value 1; values below 1 indicate overfitting), corrected for optimism by bootstrapping with 1,000 replicates. Calibration is the primary performance criterion for a model intended to inform individual decisions.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Calibration-in-the-large of the MRCP prediction model
Agreement between the mean predicted probability of difficult cannulation from the MRCP prediction model and the observed proportion, expressed as the calibration intercept with the slope fixed at 1 (ideal value 0) and estimated after bootstrap internal validation.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Estimated calibration index of the MRCP prediction model
Average squared difference between the predicted probabilities of the MRCP prediction model and the corresponding observed probabilities from a flexible (loess-smoothed) calibration curve (ideal value 0; lower is better). The calibration curve is also presented graphically.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Brier score of the MRCP prediction model
Mean squared difference between the predicted probability and the observed outcome for the MRCP prediction model (range 0 to 1; lower is better), reported unscaled and scaled to the maximum Brier score for the observed outcome proportion, and corrected for optimism by bootstrapping.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Nagelkerke R² of the MRCP prediction model
Proportion of explained variation for the MRCP prediction model on the Nagelkerke scale (range 0 to 1; higher is better), corrected for optimism by bootstrapping.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Net benefit of the MRCP prediction model at a 20% threshold probability (decision curve analysis)
Net benefit (true positives minus weighted false positives, per participant) of the MRCP prediction model at the pre-specified illustrative threshold of 20%, compared with treating all participants as difficult (universal wire-first rendezvous) and treating none. Decision curves are presented across threshold probabilities from 5% to 60%.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Adjusted odds ratios for difficult cannulation associated with each MRCP predictor in the primary model
Penalized adjusted odds ratios with 95% CI from the MRCP prediction model for the choledochoduodenal angle (per 10° reduction), a periampullary diverticulum with the papilla inside it or on its rim (Boix types I-II, versus none or type III) and maximum CBD diameter (per 1 mm).
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Sensitivity and specificity of individual MRCP measurements for difficult cannulation
Sensitivity and specificity, each with 95% CI, of every continuous MRCP morphometric measurement at its pre-specified threshold (for example, choledochoduodenal angle below 130°) and at the Youden-index optimal threshold, the latter with a bootstrap CI and flagged as data-derived. Positive and negative predictive values and likelihood ratios are reported alongside.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
MRCP prediction model performance by endoscopist experience
Optimism-corrected C-statistic and calibration slope of the MRCP prediction model in procedures performed by endoscopists with 300 or more versus fewer than 300 lifetime ERCPs.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Agreement between MRCP and endoscopy for detection of periampullary diverticulum
Cohen's kappa between MRCP-based and endoscopic detection of periampullary diverticulum, with the sensitivity and specificity of MRCP against the endoscopic view at duodenoscopy.
Time frame: Preoperative MRCP (within 14 days before surgery) and intraoperative duodenoscopy (Day 0)
Interaction between periampullary diverticulum type and choledochoduodenal angle
Exploratory likelihood-ratio test and interaction odds ratios for Boix type × choledochoduodenal angle added to the MRCP prediction model.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Incremental value of each remaining candidate MRCP predictor (exploratory extended models)
Change in optimism-corrected C-statistic, with a likelihood-ratio test, when each remaining candidate predictor (distal CBD angulation, intramural segment length, impacted distal or intramural stone, stone-to-duct ratio, papillary azimuth and Boix type III) is added singly to the MRCP prediction model; reported as exploratory and not used to modify the score.
Time frame: Predictors from the preoperative MRCP (within 14 days before surgery); outcome during the intraoperative cannulation phase (Day 0)
Plan to share: No
Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.